Thus, the exact mechanism via which MAP3K19 regulates fibroblast to myofibroblast transition in IPF patients requires further investigation particularly whether the targeting of MAP3K19 alters lung responsiveness to profibrotic mediators including several growth factors. The gene discussed is MAP3K19; the disease is idiopathic pulmonary fibrosis.